Checkpoint inhibition and melanoma: Considerations in treating the older adult Journal Article


Authors: Friedman, C. F.; Wolchok, J. D.
Article Title: Checkpoint inhibition and melanoma: Considerations in treating the older adult
Abstract: The incidence of melanoma and associated mortality rate from advanced disease in older adults is increasing over time. Checkpoint inhibitors have demonstrated a survival benefit for the treatment of stage IV or unresectable stage III disease and have become one of the standards of care. Data suggests that adults aged 65 and older benefit from treatment with checkpoint inhibitors without an increased incidence in adverse events. However, clinicians should be aware of the potential side effects of this class of medications and how to manage them in older adults. © 2017 Elsevier Ltd
Keywords: cancer survival; primary tumor; unclassified drug; clinical feature; fatigue; review; advanced cancer; diarrhea; drug safety; monotherapy; side effect; drug targeting; antineoplastic agent; medical decision making; cytotoxic t lymphocyte antigen 4 antibody; ipilimumab; cancer immunotherapy; melanoma; incidence; age; rash; alanine aminotransferase; aspartate aminotransferase; social support; adverse outcome; cytokine production; innate immunity; immunostimulation; adaptive immunity; cytotoxic t lymphocyte antigen 4; immunosuppressive treatment; functional status; immunopathology; programmed death 1 receptor; nivolumab; human; priority journal; checkpoint inhibitor; pembrolizumab; immune-related adverse events; checkpoint inhibitors; programmed death 1 inhibitor
Journal Title: Journal of Geriatric Oncology
Volume: 8
Issue: 4
ISSN: 1879-4068
Publisher: Elsevier Inc.  
Date Published: 2017-07-01
Start Page: 237
End Page: 241
Language: English
DOI: 10.1016/j.jgo.2017.04.003
PROVIDER: scopus
PUBMED: 28506536
PMCID: PMC5629004
DOI/URL:
Notes: Review -- Export Date: 2 August 2017 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Jedd D Wolchok
    701 Wolchok